Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
accomplished, Additionally, antagonizing, appointment, Aprea, APS, APTO, Bernd, BioInvent, biopharmaceutical, Biotech, Black, Bruton, calendar, CEO, Chairman, compliance, Concomitant, CryptoMedix, CSO, Department, desired, diffuse, Dr, faculty, forward, Genome, German, good, GPC, Haematologica, Harvard, hypoxia, induction, industry, letter, Mantel, Norway, notifying, Oxford, passthrough, polyploidy, practice, preceding, President, Princeton, produced, Professor, profound, RAS, regain, remote, School, Seizinger, senior, Squibb, Sweden, symbol, tenure, TSX, urgently, usage, Vaccibody, Visiting, VP, written
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view